Results 301 to 310 of about 241,082 (329)

Osteosarcoma of the pelvis [PDF]

The Journal of Bone and Joint Surgery. British volume, 1999
Over a 25-year period we have treated 36 patients with osteosarcoma of the pelvis. Of the tumours, 24 (67%) were primary osteosarcomas and 12 (33%) arose either after irradiation or in association with Paget’s disease. Six patients had a hindquarter amputation and 12 were treated by a limb-salvage procedure with intrapelvic excision.
M C, Parry, M, Laitinen, J, Albergo, L, Jeys, S, Carter, C L, Gaston, V, Sumathi, R J, Grimer   +7 more
openaire   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Advancing therapy for osteosarcoma

Nature Reviews Clinical Oncology, 2021
Jonathan D Gill, R. Gorlick
semanticscholar   +1 more source

Targeted therapy for osteosarcoma: a review

Journal of Cancer Research and Clinical Oncology, 2023
Shizhe Li, He-Cheng Zhang, Jinxin Liu, Guanning Shang   +3 more
semanticscholar   +1 more source

Osteosarcoma of the Carpus

Journal of Hand Surgery, 1988
A case of osteosarcoma of the carpus is reported and the relevant literature reviewed.
S. C. Harris, N. R. M. Kay, D. R. Bickerstaff   +2 more
openaire   +3 more sources

Osteosarcoma of the pelvis

European Journal of Surgical Oncology (EJSO), 2004
To describe the outcomes of a large number of patients with pelvic osteosarcoma, and to define the guidelines for appropriate treatment.We reviewed 60 consecutive patients with primary pelvic high-grade osteosarcoma. The tumour involved the whole hemipelvis in 15 cases, while the most common location was the iliac wing in 29 cases (48.3%): 25 of these ...
DONATI, DAVIDE MARIA, GIACOMINI S., GOZZI E., FERRARI L., SANGIORGI A., TIENGHI A., DeGROOT H., BERTONI, FRANCO, BACCHINI P., BACCI G., MERCURI, MARIO   +10 more
openaire   +4 more sources

New Horizons in the Treatment of Osteosarcoma.

New England Journal of Medicine, 2021
P. Meltzer, L. Helman
semanticscholar   +1 more source

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.

Journal of Clinical Oncology, 2019
PURPOSE SARC024 is a phase II clinical trial of the multikinase inhibitor regorafenib in specific sarcoma subtypes, including advanced osteosarcoma. We hypothesized that regorafenib would improve progression-free survival (PFS) in patients with sarcoma ...
L. Davis, V. Bolejack, C. Ryan, K. Ganjoo, E. Loggers, S. Chawla, M. Agulnik, M. Livingston, D. Reed, V. Keedy, D. Rushing, S. Okuno, D. Reinke, R. Riedel, S. Attia, L. Mascarenhas, R. Maki   +16 more
semanticscholar   +1 more source

The Epidemiology of Osteosarcoma

2009
Osteosarcoma derives from primitive bone-forming mesenchymal cells and is the most common primary bone malignancy. The incidence rates and 95% confidence intervals of osteosarcoma for all races and both sexes are 4.0 (3.5-4.6) for the range 0-14 years and 5.0 (4.6-5.6) for the range 0-19 years per year per million persons.
G. Ottaviani, N. Jaffe
openaire   +4 more sources

Proteomics of osteosarcoma

Expert Review of Proteomics, 2014
Osteosarcoma (OS) is the most common primary malignant tumor of bone and the third most common cancer in childhood and adolescence. Nowadays, early diagnosis, drug resistance and recurrence of the disease represent the major challenges in OS treatment.
Bernardini, Giulia, Laschi, Marcella, Geminiani, Michela, Santucci, Annalisa   +3 more
openaire   +4 more sources

Update on Osteosarcoma

Current Oncology Reports, 2021
Rebekah Belayneh, Mitchell S. Fourman, Sumail Bhogal, K. Weiss   +3 more
semanticscholar   +1 more source